Astana Biomed Group, an authorized Abcam distributor in Central Asia

FITC Anti-CD3 zeta (phospho Y83) antibody [EP776(2)Y] (ab237453)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • FITC Rabbit monoclonal [EP776(2)Y] to CD3 zeta (phospho Y83)
  • Suitable for: ICC, Flow Cyt
  • Reacts with: Human
  • Conjugation: FITC. Ex: 493nm, Em: 528nm

Overview

  • Product name

    FITC Anti-CD3 zeta (phospho Y83) antibody [EP776(2)Y]
    See all CD3 zeta primary antibodies

  • Description

    FITC Rabbit monoclonal [EP776(2)Y] to CD3 zeta (phospho Y83)

  • Host species

    Rabbit

  • Conjugation

    FITC. Ex: 493nm, Em: 528nm

  • Specificity

    This antibody detects CD3 zeta phosphorylated on tyrosine 83.

  • Tested Applications & Species

    Application Species
    Flow Cyt
    Human
    ICC
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • ICC: Pervanadate treated Jurkat cells. Flow Cyt: Pervanadate treated Jurkat cells.

  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

  • Form

    Liquid

  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. Store In the Dark.

  • Storage buffer

    pH: 7.40
    Preservative: 0.02% Sodium azide
    Constituents: 30% Glycerol, 1% BSA, PBS
  • Concentration information loading...

  • Purity

    Immunogen affinity purified

  • Clonality

    Monoclonal

  • Clone number

    EP776(2)Y

  • Isotype

    IgG

  • Research areas

Images

  • Immunocytochemistry - FITC Anti-CD3 zeta (phospho Y83) antibody [EP776(2)Y] (ab237453)
    Immunocytochemistry - FITC Anti-CD3 zeta (phospho Y83) antibody [EP776(2)Y] (ab237453)

    ab237453 staining CD3 zeta (phospho Y83) in Jurkat cells +/- pervanadate ( 1mM, 30min). The cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, then incubated ab237453 at 1/50 dilution (shown in green). Counterstained with ab195889, anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594), (shown in red). Nuclear DNA was labelled with DAPI (shown in blue).

  • Flow Cytometry - FITC Anti-CD3 zeta (phospho Y83) antibody [EP776(2)Y] (ab237453)
    Flow Cytometry - FITC Anti-CD3 zeta (phospho Y83) antibody [EP776(2)Y] (ab237453)

    Flow cytometry overlay histogram showing Jurkat + pervanadate ( 1mM, 30min)(Red) / Untreated control (Green) stained with ab237453. The cells were fixed with 4 % formaldehyde (10 min). The cells were incubated in 1x PBS containing 10% normal goat serum to block non-specific protein-protein interaction followed by the antibody (ab237453).

    Isotype control antibody (Black) was Rabbit IgG, monoclonal [EPR25A] - Isotype Control (FITC) (ab223339) used at the same concentration and conditions as the primary antibody.

    Unlabelled sample without incubation with primary antibody and secondary antibody (Blue) was also used as a control.

     

  • FITC Anti-CD3 zeta (phospho Y83) antibody [EP776(2)Y] (ab237453)
    FITC Anti-CD3 zeta (phospho Y83) antibody [EP776(2)Y] (ab237453)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

© 2021 Astana Biomed Group LLP. All rights reserved.